古塞奇尤单抗在银屑病2期和3期研究中的剂量-暴露-反应关系
本文基于古塞奇尤单抗治疗中重度银屑病的2期和3期研究,分析剂量-反应与暴露-反应关系以优化剂量选择。2期显示5-100mg剂量范围内PASI和PGA呈阳性剂量反应,稳态谷浓度≥0.67 μg/mL患者疗效最高;100mg每8周方案被选入3期,3期第28周72.5%患者达到该浓度,并伴高应答率。结论认为100mg每8周为最佳方案。
要点
- 2期显示古塞奇尤单抗5-100mg剂量范围内PASI和PGA呈阳性剂量反应。
- 稳态谷浓度≥0.67 μg/mL与最高疗效相关,该浓度下PGA 0/1达90.0%。
- 3期第28周72.5%患者达到≥0.67 μg/mL,支持100mg每8周为最佳方案。
核心结论
- 基于2期剂量-暴露-反应关系选定的100mg每8周方案,在3期多数患者中产生了与高水平疗效相关的目标血清浓度。
- 3期数据进一步确认古塞奇尤单抗100mg每8周是治疗中重度银屑病的最佳给药方案。
研究设计与样本
- 研究采用2期和3期研究(VOYAGE 1和VOYAGE 2)数据,评估古塞奇尤单抗的剂量-反应与暴露-反应关系。
- 血清古塞奇尤单抗浓度采用经验证的免疫分析法测定。
- 疗效评估包括医师总体评估(PGA)、研究者总体评估(IGA)和银屑病面积与严重程度指数(PASI)。
主要发现
- 2期研究中,5mg至100mg剂量方案对PASI和PGA观察到阳性剂量-反应关系。
- 暴露-反应分析显示,稳态谷血清古塞奇尤单抗浓度≥0.67 μg/mL的患者达到最高疗效水平(PGA 0/1:90.0%;PGA 0:70.0%)。
- 100mg每8周方案在2期安全且耐受良好,在所有 studied 方案中提供最高血清浓度,并被选入3期。
- 3期第28周,72.5%的患者达到古塞奇尤单抗浓度≥0.67 μg/mL。
- 达到该浓度的患者第28周应答率为IGA 0/1:91.2%,IGA 0:55.3%,PASI 90:83.8%,PASI 100:49.1%。
关键数值与推荐
- 2期剂量范围:5mg至100mg。
- 稳态谷血清古塞奇尤单抗浓度阈值:≥0.67 μg/mL。
- 3期第28周达到浓度≥0.67 μg/mL的患者比例为72.5%。
- 达到浓度≥0.67 μg/mL患者第28周应答率:PGA 0/1 90.0%(2期);IGA 0/1 91.2%、IGA 0 55.3%、PASI 90 83.8%、PASI 100 49.1%(3期)。
临床怎么用
- 古塞奇尤单抗100mg每8周给药方案可依据2期剂量-暴露-反应关系优化中重度银屑病的剂量选择。
- 3期数据支持100mg每8周方案在多数患者中达到与高水平疗效相关的目标血清浓度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guselkumab is an anti-interleukin-23 monoclonal antibody for the treatment of moderate-to-severe psoriasis. OBJECTIVE: To evaluate the association between dose-response and exposure-response of guselkumab in Phase 2 and Phase 3 studies to optimize dose selection. METHODS: Serum guselkumab concentrations in Phase 2 and Phase 3 studies (VOYAGE 1 and VOYAGE 2) were measured using a validated immunoassay. Efficacy assessments included Physician's Global Assessment (PGA), Investigator's Global Assessment (IGA) and Psoriasis Area and Severity Index (PASI). RESULTS: In Phase 2, a positive dose-response relationship was observed for PASI and PGA (5-mg through 100-mg dose regimens). Exposure-response analysis showed that patients with steady-state trough serum guselkumab concentrations ≥0.67 μg/mL achieved the highest levels of efficacy (PGA 0/1: 90.0%; PGA 0: 70.0%). The guselkumab 100-mg every 8-week (q8w) dose regimen, safe and well-tolerated in Phase 2, provided the highest serum guselkumab concentrations among all regimens studied and was selected for Phase 3. In Phase 3, 72.5% of patients achieved guselkumab concentrations ≥0.67 μg/mL at week 28, the level associated with the highest clinical responses in Phase 2, with patients achieving response rates of IGA 0/1: 91.2%, IGA 0: 55.3%, PASI 90: 83.8% and PASI 100: 49.1% at week 28. CONCLUSION: The 100-mg guselkumab q8w dose regimen, based on the dose-exposure-response relationship from the Phase 2 study, produced the target serum concentration associated with high-level efficacy in the majority of patients in Phase 3. Phase 3 data further confirmed that guselkumab 100mg q8w is the optimum dosing regimen for treating patients with moderate-to-severe psoriasis.
引用
- Lebwohl M, Langley RG, Zhu Y, et al. Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis. J Eur Acad Dermatol Venereol. 2019. PMID: 31077471. doi:10.1111/jdv.15668
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。